Test for genetic markers that influence highly active antiretroviral therapy (HAART) in HIV-positive patients.

Highly active retroviral therapy (HAART) is a very effective treatment for HIV-positive patients. Allelic variants of certain proteins have been associated with successful HAART. The PGX-HIV StripAssay® identifies variants in genes known to be relevant for effective HAART.

 

PGX-HIV

 

  • HAART has brought about substantial improvements to HIV-positive patients and has led to a significant reduction in AIDS-related mortality in countries with access to the treatment.
  • Allelic variants of the multidrug transporter P-glycoprotein 1 (MDR1), cytochrome P450 isozyme 2D6 (CYP2D6), and the C-C chemokine receptor 5 (CCR5) are known to be associated with the best possible outcome of HAART.
  • Identification of relevant genetic variations supports better guidance of HIV therapy.
  • The PGX-HIV StripAssay® identifies genetic variants, which influence the efficacy of HAART, and can help to adjust therapy to individual needs.

 

ProductREFUnit SizeIFUBrochure
PGX-HIV StripAssay®4-71020 tests

PDF

PDF